Scientific Sessions 2025  /  Multimodality Imaging for Diagnosis, Risk Stratification and Management of Hypertrophic Cardiomyopathy  /  Unmasking a masquerader: Leveraging multimodality imaging to characterize phenocopies
Logo

American Heart Association

  42
  0

Final ID:

Unmasking a masquerader: Leveraging multimodality imaging to characterize phenocopies

  • Masri, Ahmad  ( OHSU , Portland , Oregon , United States )
    • Author Disclosures:
    Ahmad Masri: DO have relevant financial relationships ; Consultant: Cytokinetics, BMS, BridgeBio, Pfizer, Ionis, Lexicon, Attralus, Alnylam, Haya, Alexion, Akros, Edgewise, Rocket, Lexeo, Prothena, BioMarin, AstraZeneca, Avidity, Neurimmune, and Tenaya.:Active (exists now) ; Research Funding (PI or named investigator): Pfizer, Ionis, Attralus, Cytokinetics and Janssen. :Active (exists now)
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Multimodality Imaging for Diagnosis, Risk Stratification and Management of Hypertrophic Cardiomyopathy

Friday, 11/07/2025 , 08:00AM - 09:15AM

Cardiovascular Seminar

More abstracts on this topic:
Opening Remarks

Owens Anjali

Sudden death risk assessment and multimodality imaging: Reconciling recommendations across the pond

Raman Betty

More abstracts from these authors:
Predicted Peak Oxygen Consumption in Patients with Hypertrophic Cardiomyopathy is Highly Variable by Sex and Predictive Equation

Tandon Hannah, Jahan Israt, Burton Yunwoo, Petek Bradley, Masri Ahmad

Prevalence and Characteristics of Hypertrophic Cardiomyopathy Phenotype in Patients with Cardiac Sarcoidosis

Zia Abdul, Lal Mallika, Nazer Babak, Levin Benjamin, Masri Ahmad

You have to be authorized to contact abstract author. Please, Login
Not Available